09/11/2014 01:54 am ET Updated Sep 11, 2014

Ebola Drug ZMapp: This DARPA Program Could Get It To Africa

DOMINIQUE FAGET via Getty Images

Last week, as experts assembled at the World Health Organization headquarters in Geneva to discuss the Ebola outbreak in West Africa, there was a glaring absence in the public discourse: an accurate assessment of the U.S. government’s capacity to produce ZMapp, one of the experimental drugs under discussion for speeded approval. The drug, a cocktail of three monoclonal antibodies that has now been used in the treatment of at least seven Ebola patients, five of whom survived, has the potential to be an exceptional therapy against the virus. But the world’s supply is currently exhausted, and production of even several dozen additional doses of the drug remains months away.

Read more on New Republic